Cargando…
Proteomics of resistance to Notch1 inhibition in acute lymphoblastic leukemia reveals targetable kinase signatures
Notch1 is a crucial oncogenic driver in T-cell acute lymphoblastic leukemia (T-ALL), making it an attractive therapeutic target. However, the success of targeted therapy using γ-secretase inhibitors (GSIs), small molecules blocking Notch cleavage and subsequent activation, has been limited due to de...
Autores principales: | Franciosa, Giulia, Smits, Jos G. A., Minuzzo, Sonia, Martinez-Val, Ana, Indraccolo, Stefano, Olsen, Jesper V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097059/ https://www.ncbi.nlm.nih.gov/pubmed/33947863 http://dx.doi.org/10.1038/s41467-021-22787-9 |
Ejemplares similares
-
Histone deacetylase 6 controls Notch3 trafficking and degradation in T-cell acute lymphoblastic leukemia cells
por: Pinazza, Marica, et al.
Publicado: (2018) -
Targeting NOTCH1 in combination with antimetabolite drugs prolongs life span in relapsed pediatric and adult T-acute lymphoblastic leukemia xenografts
por: Minuzzo, Sonia, et al.
Publicado: (2023) -
Dissecting molecular mechanisms of resistance to NOTCH1-targeted therapy in T-cell acute lymphoblastic leukemia xenografts
por: Agnusdei, Valentina, et al.
Publicado: (2020) -
An immediate transcriptional signature associated with response to the histone deacetylase inhibitor Givinostat in T acute lymphoblastic leukemia xenografts
por: Pinazza, M, et al.
Publicado: (2016) -
SHMT inhibition is effective and synergizes with methotrexate in T-cell acute lymphoblastic leukemia
por: García-Cañaveras, Juan C., et al.
Publicado: (2020)